Comparative Pharmacology
Head-to-head clinical analysis: BETAPACE AF versus NADOLOL AND BENDROFLUMETHIAZIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BETAPACE AF versus NADOLOL AND BENDROFLUMETHIAZIDE.
BETAPACE AF vs NADOLOL AND BENDROFLUMETHIAZIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sotalol is a class III antiarrhythmic agent that also has non-cardioselective beta-adrenergic receptor blocking activity. It prolongs the cardiac action potential duration by blocking potassium channels (IKr), thereby prolonging the QT interval and refractory periods.
Nadolol is a nonselective beta-adrenergic receptor antagonist that blocks beta1 and beta2 receptors, reducing heart rate, myocardial contractility, and blood pressure. Bendroflumethiazide is a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, increasing excretion of sodium and water and reducing plasma volume.
80 mg orally twice daily. For atrial fibrillation/flutter, initiate at 80 mg twice daily; may increase after 2-3 days to 120 mg twice daily if needed. Maximum 120 mg twice daily.
Nadolol 40–80 mg orally once daily; bendroflumethiazide 2.5–5 mg orally once daily. Dose titration based on blood pressure response.
None Documented
None Documented
Terminal elimination half-life: 12 hours (range 10–20 hours) in patients with normal renal function; prolonged in renal impairment (up to 42 hours in severe impairment).
Nadolol: 14–24 h (mean 20 h); allows once-daily dosing. Bendroflumethiazide: 3–4 h (terminal); clinical duration longer due to prolonged action on distal tubule.
Primarily renal (unchanged drug and metabolites); approximately 40% excreted as unchanged sotalol in urine, with additional metabolites via fecal route (~10%). Biliary excretion minimal (<5%).
Nadolol: ~70% renal unchanged, ≤5% fecal. Bendroflumethiazide: ~30% renal unchanged, ~70% renal as metabolites; minimal biliary.
Category C
Category C
Beta-Blocker
Beta-Blocker